Clinical trials: Attention-Deficit and Hyperactivity Disorder
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17
The purpose of this study is to determine the efficacy of SPD503 compared to placebo in the treatment of children and adolescents aged 6-17 with ADHD.
- Trial name
- NCT00150618
- Testing
- SPD503 (1 mg), SPD503 (2 mg), SPD503 (3 mg)
- Volunteers
- 324 people
- Sponsor
- Shire
ADHD, Sleep
Sleep IntervEntion as Symptom Treatment for ADHD
Up to 72% of adolescents with ADHD portray sleep problems. The most common sleep difficulties in adolescents with ADHD are initial insomnia, nocturnal awakenings, non-restorative or restless sleep.
- Conditions
- ADHD, Sleep, Adolescents, CBT
- Trial name
- SIESTA (NCT04723719)
- Testing
- SIESTA, Treatment as usual for ADHD
- Where
- Belgium
- Volunteers
- 92 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Attention Deficit Hyperactivity Disorder
NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)
The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD
- Trial name
- NCT01654250
- Testing
- NWP09
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- Pfizer
Attention Deficit Hyperactivity Disorder (ADHD)
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12…
- Trial name
- NCT01835548
- Testing
- NT0102
- Where
- 4 sites in United States
- Volunteers
- 87 people
- Sponsor
- Neos Therapeutics, Inc
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of impulsive aggression in patients with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with standard…
- Trial name
- NCT02618434
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 32 sites in United States
- Volunteers
- 297 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Disorder With Hyperactivity
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety and efficacy of Osmotic Release Oral System (OROS) methylphenidate in participants with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT01012622
- Testing
- Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride
- Volunteers
- 142 people
- Sponsor
- Janssen Korea, Ltd., Korea
Attention Deficit/Hyperactivity Disorder
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT01259492
- Testing
- Ritalin LA 20 mg, Ritalin LA 30 mg
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 725 people
- Sponsor
- Novartis Pharmaceuticals
ADHD
ADHD Treatment for Latino Families
The current pilot study aims to close the existing gap in our knowledge about effective psychosocial treatments for Latino families by providing preliminary data regarding the acceptability and efficacy of a culturally-modified…
- Trial name
- NCT02317692
- Testing
- Parent training
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- Marquette University
Attention Deficit Disorder With Hyperactivity
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
This is a randomized, double-blind, placebo-controlled, parallel-group study of NFC-1 versus placebo in adolescents with ADHD who have genetic disorders impacting mGluRs.
- Trial name
- NCT02777931
- Testing
- NFC-1
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Attention Deficit Hyperactivity Disorder
New Technologies to Help Manage ADHD
Cluster randomized controlled trial to evaluate the general effectiveness of intervention compared to control on medication continuity as measured by prescriptions written and other more proximal outcomes during the first six…
- Trial name
- NCT02390791
- Testing
- enhanced myADHDportal.com, treatment as usual standard portal
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Hyperactivity Disorder
Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a two-arm, parallel, randomized, double-blind, placebo-controlled Phase 4 multicenter trial to compare the whole day efficacy of atomoxetine versus placebo in children aged 6 through 12 years with…
- Trial name
- NCT00546910
- Testing
- Atomoxetine
- Where
- 16 sites in Germany
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
Conduct Disorder, Conduct Disorders in Children
Impact VR: An Emotion Recognition and Regulation Training Program for Youth With CD
Conduct disorder (CD) is one of the most prevalent childhood psychiatric disorders. Unfortunately, there are limited treatments available for CD.
- Conditions
- Conduct Disorder, Conduct Disorders in Children, Conduct Disorders in Adolescence, Callous-Unemotional Traits
- Trial name
- NCT06301516
- Testing
- Virtual Reality, Comparative Control
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Virginia Commonwealth University
Attention-Deficit/Hyperactivity Disorder
Trigeminal Nerve Stimulation for Attention Deficit Hyperactivity Disorder (ADHD)
This proposal seeks to obtain preliminary data on the potential efficacy, tolerability, and feasibility of trigeminal nerve stimulation (TNS) as a treatment for Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01388530
- Testing
- EMS 7500 Digital Muscle Stimulator
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, Los Angeles
Neurofibromatosis 1
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1
Children with neurofibromatosis type 1 (NF1) commonly suffer from the effects of cognitive, behavioral, and motor impairments. At present, there is no specific treatment for this NF1 complication.
- Trial name
- DoDNAC (NCT04481048)
- Testing
- N-Acetyl cysteine
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
ADHD, Substance Abuse
Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)
The purpose of this study is to determine the efficacy of osmotic-release methylphenidate (OROS-MPH) versus placebo for the treatment of ADHD in adolescents with SUD.
- Trial name
- NCT00264797
- Testing
- Methylphenidate (OROS-MPH)
- Where
- 12 sites in United States
- Volunteers
- 303 people
- Sponsor
- University of Cincinnati
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
Children between the ages of 6-12 years who are diagnosed with impulsive aggression comorbid with ADHD and have participated in the 810P301 or 810P302 study were invited to participate in this study.
- Trial name
- NCT02691182
- Testing
- SPN-810
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
Dasotraline Pediatric Extension Study
This is an open label 26 week extension study for subjects who completed SEP360-202.
- Trial name
- NCT02457819
- Testing
- Dasotraline
- Where
- 36 sites in United States
- Volunteers
- 237 people
- Sponsor
- Sumitomo Pharma America, Inc.
Conduct Disorder, Oppositional Defiant Disorder
Behavioral Treatment for Children With Conduct Problems and Callous-Unemotional Traits
The purpose of this study is to modify behavior therapy so that it is optimized for children with conduct problems and callous-unemotional traits by emphasizing reward components and de-emphasizing punishment components.
- Trial name
- NCT01362946
- Testing
- Reward-Emphasized Treatment, Standard Treatment
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Florida International University
Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD
The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA).
- Trial name
- NCT03638466
- Testing
- Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Conduct Disorder
Trial of Aripiprazole in the Treatment of CD in Adolescents
The proposed study will be a 6-week open label study evaluating aripiprazole in the treatment of 12 male post-pubertal adolescents (13-17 years, Tanner Stage 4) diagnosed with conduct disorder.
- Trial name
- NCT00250705
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Iowa